Stock CORT CORCEPT THERAPEUTICS INCORPORATED
Add to a list
To use this feature you must be a member
Log inSign up

All News Corcept Therapeutics Incorporated

Equities

CORT

US2183521028

Market Closed - Nasdaq
Other stock markets
 16:00:00 2024-05-10 EDT 		5-day change 1st Jan Change
27.04 USD +1.65% Intraday chart for Corcept Therapeutics Incorporated +10.28% -16.75%
05-02 Truist Lifts Corcept Therapeutics' PT to $44 From $42 After Raised Kolym Guidance, Keeps Buy Rating MT
05-01 Earnings Flash (CORT) CORCEPT THERAPEUTICS INCORPORATED Reports Q1 EPS $0.25, vs. Street Est of $0.22 MT

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Truist Lifts Corcept Therapeutics' PT to $44 From $42 After Raised Kolym Guidance, Keeps Buy Rating
MT
Earnings Flash (CORT) CORCEPT THERAPEUTICS INCORPORATED Reports Q1 EPS $0.25, vs. Street Est of $0.22
MT
Transcript : Corcept Therapeutics Incorporated, Q1 2024 Earnings Call, May 01, 2024
Corcept: Q1 Earnings Snapshot
AQ
Corcept Therapeutics Incorporated Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Corcept Therapeutics Announces First Quarter Financial Results and Provides Corporate Update
GL
Corcept Therapeutics Announces First Quarter Financial Results and Provides Corporate Update
AQ
Corcept Completes Enrollment in Phase 4 CATALYST Trial
GL
Corcept Therapeutics Incorporated Completes Enrollment in Phase 4 Catalyst Trial
CI
Corcept Therapeutics to Announce First Quarter Financial Results, Provide Corporate Update and Host Conference Call
GL
Corcept Announces Positive Results from Open-Label Portion of Pivotal Phase 3 GRACE Trial in Patients with Cushing's syndrome
AQ
Corcept Announces Positive Results From Open-Label Portion of Pivotal Phase 3 GRACE Trial in Patients With Cushing’s Syndrome
GL
Corcept Therapeutics Incorporated Announces Positive Results from Open-Label Portion of Pivotal Phase 3 GRACE Trial in Patients with Cushing?s Syndrome
CI
Corcept Completes Enrollment in Phase 2 DAZALS Trial in Patients With Amyotrophic Lateral Sclerosis (ALS)
GL
Corcept Completes Enrollment in Phase 2 Dazals Trial in Patients with Amyotrophic Lateral Sclerosis
CI
Corcept Completes Enrollment in Pivotal Phase 3 Rosella Trial of Relacorilant in Patients With Platinum-Resistant Ovarian Cancer
GL
Corcept Therapeutics Incorporated Completes Enrollment in Pivotal Phase 3 Rosella Trial of Relacorilant in Patients With Platinum-Resistant Ovarian Cancer
CI
Corcept Completes Enrollment in Phase 3 Gradient Trial of Relacorilant in Patients With Adrenal Cushing’s Syndrome
GL
Corcept Therapeutics Incorporated Completes Enrollment in Phase 3 Gradient Trial of Relacorilant in Patients with Adrenal Cushing's Syndrome
CI
Corcept Therapeutics Insider Sold Shares Worth $430,475, According to a Recent SEC Filing
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. CORT Stock
  4. News Corcept Therapeutics Incorporated
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW